( Toronto:RVX )

News from Resverlogix Corp. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 17, 2017, 07:00 ET Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Mar 15, 2017, 07:00 ET Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

CALGARY, March 15, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the receipt of a Notice of...


Feb 23, 2017, 07:00 ET Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

Protocol comments and recommendations incorporated CALGARY, Feb. 23, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:...


Feb 13, 2017, 07:00 ET Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

Emergence of new potential indications for apabetalone (RVX-208) via third party research CALGARY, Feb. 13, 2017 /PRNewswire/ - Resverlogix Corp....


Jan 23, 2017, 07:00 ET Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments

Several Key Proteins That Drive Kidney (Renal) Disease and Dialysis Risk are Downregulated After a Single Dose of Apabetalone CALGARY, Jan. 23,...


Jan 23, 2017, 07:00 ET Resverlogix proporciona resultados revolucionarios en pacientes con discapacidad renal severa

Varias proteínas clave que impulsan la enfermedad del riñón (renal) y el riesgo de diálisis están poco reguladas tras una sola dosis de...


Jan 05, 2017, 17:43 ET Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA

CALGARY, Jan. 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Company") (TSX:RVX) today announces its participation in the 9th...


Dec 15, 2016, 23:24 ET Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders

CALGARY, Dec. 15, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX: RVX) today announced that, at its annual and...


Dec 13, 2016, 18:28 ET Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

CALGARY, Dec. 13, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its unaudited...


Dec 05, 2016, 12:13 ET Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

A data review by the independent Data Safety Monitoring Board resulted in a recommendation for the BETonMACE trial to continue as planned without...


Nov 17, 2016, 08:00 ET Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

The successful completion of this Phase 1 pharmacokinetic (PK) trial in patients with severe renal impairment clears the path for the Company to...


Oct 06, 2016, 18:15 ET Resverlogix Announces Annual and Special Meeting of Shareholders

TORONTO, Oct. 6, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has rescheduled its...


Oct 04, 2016, 07:00 ET Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease

CALGARY, Oct. 4, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) will host R&D update events in New York, NY...


Sep 14, 2016, 18:35 ET Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis

CALGARY, Sept. 14, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has filed its...


Sep 12, 2016, 07:00 ET Resverlogix Announces Participation in Upcoming Conferences

CALGARY, Sept. 12, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce its participation in the...


Aug 30, 2016, 05:32 ET Resverlogix hospeda un simposio para debatir acerca del papel de la inhibición BET

- Resverlogix hospeda un simposio para debatir acerca del papel de la inhibición BET en los riesgos modificadores cardiovasculares en el...


Aug 29, 2016, 11:03 ET Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of...


Aug 11, 2016, 07:35 ET Resverlogix anuncia la recomendación positiva del estudio en Fase 3 de Apabetalone (RVX-208)

- Resverlogix anuncia la recomendación positiva del consejo de control de seguridad de datos del estudio en Fase 3 de Apabetalone...


Aug 11, 2016, 07:00 ET Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)

A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned...


Jul 27, 2016, 18:43 ET Resverlogix Files 2016 Year-End Disclosure Documents

CALGARY, July 27, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it filed its audited...


Jul 22, 2016, 13:43 ET Resverlogix anuncia la dosificación a los primeros dos pacientes en programas renales y huérfanos ampliados

El comienzo de este ensayo de fase 1 farmacocinético (PK) en pacientes con deterioro renal severo es el primero de una serie de ensayos...


Jul 21, 2016, 14:35 ET Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs

The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical...


Jun 09, 2016, 14:15 ET Resverlogix Announces Corporate Update Webcast

CALGARY, June 9, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces it will be hosting a corporate update via webcast...


Jun 02, 2016, 08:00 ET Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016

CALGARY, June 2, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that findings of a...


May 24, 2016, 18:54 ET Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

"Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement...